RAC1 activity is required for ER protein stability and estrogen-stimulated ER transcriptional activity in ER+ BC, likely explaining why the Rac inhibitor EHT 1864 represses ER target genes and is potentially helpful in combating endocrine resistance [28], utilizing a mechanism distinct from the action of anti-estrogens. This evidence concerns the gene RAC1 and breast cancer.